KRYS Earnings & Financial Statements
Krystal Biotech, Inc.
$327.60
+$5.32(+1.65%)
58
Overall
65
Value
50
Tech
60
Quality
Market Cap
$9.54B
Volume
58.87K
52W Range
$168.34 - $382.54
Target Price
$389.80
KRYS earnings and financial statements: Krystal Biotech, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KRYS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $389.13M | $290.51M | $50.70M | - | - |
| Cost of revenue | $23.05M | $20.06M | $3.09M | - | - |
| Operating income | $161.29M | $65.75M | -$109.73M | -$145.20M | -$68.28M |
| EBITDA | $167.85M | $72.46M | -$3.82M | -$146.40M | -$66.23M |
| Net income | $204.83M | $89.16M | $10.93M | -$139.97M | -$69.57M |
| EPS (diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.33B | $1.06B | $818.36M | $558.45M | $626.29M |
| Total liabilities | $114.23M | $109.46M | $39.71M | $36.22M | $32.72M |
| Shareholders’ equity | $1.22B | $946.38M | $778.64M | $522.23M | $593.58M |
| Cash and equivalents | $496.30M | $344.87M | $358.33M | $161.90M | $341.25M |
| Long-term debt | $7.57M | $6.04M | $6.62M | $7.37M | $6.98M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $200.87M | $123.42M | -$88.80M | -$100.57M | -$47.94M |
| Capital expenditure | -$11.52M | -$4.24M | -$11.80M | -$52.98M | -$68.34M |
| Free cash flow | $188.91M | $119.18M | -$100.60M | -$153.55M | -$116.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KRYS | $327.60 | +1.7% | 58.87K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |